Munich-based industrial holding ADCURAM Group AG and its Nuvisan Pharma Holding GmbH subsidiary have divested their Clinical Drug Development activities to Linical Co. Ltd. a leading Japanese clinical research organization (CRO). The complex carve out transaction was settled with economic effect as of 30 November 2014. Continue reading